New Alzheimer’s drug: what you need to know about donanemab’s promising trial results
New Alzheimer’s drug: what you need to know about donanemab’s promising trial results: Donanemab targets amyloid plaques in the brain. Signal Scientific Visuals/ Shutterstock American pharmaceutical company Eli Lilly announced last week that it had seen encouraging clinical trial results of its new Alzheimer’s medication. According to the company, their experimental drug, donanemab, was shown …
